SWOG
http://swog.org

Policy Memorandum No. 12

Subject: Registration and Treatment Policies
Departments Affected: All

Original Release Date: July 1985
Revision Date: April 2018

SWOG
REGISTRATION AND TREATMENT POLICIES

1. Registrations

Patients must be registered with the Statistics and Data Management Center (SDMC) prior to initiation of treatment. Registration must take place no more than one working day prior to the planned start of treatment except for studies in which surgery or radiation therapy are the first treatment modalities following registration (including studies requiring placement of a Hickman or port catheter) or as otherwise stated in the protocol. Allowances are made for scheduling for these procedures. However, actual scheduling of radiotherapy or surgery should take place immediately following registration with the SDMC. If scheduling cannot be done immediately (e.g., patient unsure when they will be available, surgeon out of town for extended time), registration should be delayed. Direct patient registration through the Oncology Patient Enrollment Network (OPEN) must be performed by NCTN and NCORP Members and Affiliates (with permission of their Member), and some Special Members, at any time with the exception of scheduled maintenance periods.

Late registrations (after start of treatment) will not be accepted. It is required that institutions register patients online to avoid any possible delays. For registrations to SWOG-coordinated non-randomized studies on holidays and weekends (or after regular business hours) and/or the site is unable to access the online registration program, the institution must call the Data Operations Center leaving a voice mail message on the day treatment is to begin. The caller must state the name of the institution, investigator, CRA, patient initials, disease site and study number. A call must then be placed to the Data Operations Center on the next working day to register these cases.

In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday four weeks later would be considered Day 28. This allows for efficient patient scheduling without exceeding the guidelines. If Day 28 (the target date) falls on a weekend or holiday, the limit may be extended to the next working day.

2. Eligibility Exceptions

The SDMC will make no exceptions to the eligibility criteria as written in the protocol without a written amendment to the protocol from the Operations Office. Amendments must be recommended by the Study Chair, approved by the Disease Committee Chair, the Committee’s Executive Officer, the Statistician of record, and the NCI. Once approved at all levels, the amendment to the protocol is circulated to the Group and the Statistical Center modifies their registration routine. No one in the Group is authorized to make exceptions to eligibility criteria unless an error is discovered in the protocol relating to the exception.

3. Cancellations

Under rare circumstances, patient registrations may be cancelled. Cancellations are approved at the discretion of the Group Statistician.
4. **Affiliate**

Affiliate registrations must be performed through the Member institution unless the Affiliate has been designated a “free-standing” affiliate, or has been given direct registration privileges via the web by its Member.

5. **Non-SWOG Studies**

These registration policies apply to all patients registered on studies managed by the SWOG SDMC, regardless of who is registering the patient. For studies managed by another SDMC within the National Clinical Trials Network, the registration policies of that SDMC take precedence; however, if exceptions to the eligibility criteria as written in the protocol are made by the other SDMC, the institution must obtain this in writing and maintain as a part of their source documentation so it is available should it be questioned during audit.

6. **Treatment**

The registering investigator must accept full responsibility for each patient’s treatment, monitoring and dose modifications, as well as for providing adequate documentation of all treatment, toxicities, response and follow-up. The registering investigator is also responsible for all quality assurance requirements and drug accountability record forms.

Patients must not be registered if they will not be seen at the institution reported as the ‘treating institution’. In rare cases, circumstances developing after registration may require that a patient receive care from a non-SWOG physician. This does not release the registering investigator from the responsibilities noted above.

The treating institution is responsible for performing Institutional Review Board functions, i.e., initial and continuing review, consent form, and adverse drug reaction reporting.